Review Article| Volume 100, ISSUE 3, P523-534, June 2020

Management of Gastric Adenocarcinoma for General Surgeons

Published:March 18, 2020DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Torre L.A.
        • Bray F.
        • Siegel R.L.
        • et al.
        Global cancer statistics, 2012.
        CA Cancer J Clin. 2015; 65: 87-108
        • Miller K.D.
        • Nogueira L.
        • Mariotto A.B.
        • et al.
        Cancer treatment and survivorship statistics, 2019.
        CA Cancer J Clin. 2019; 69: 363-385
        • Ikoma N.
        • Cormier J.N.
        • Feig B.
        • et al.
        Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: analysis of the National Cancer Data Base, 2006-2014.
        Cancer. 2018; 124: 998-1007
        • Suh Y.S.
        • Yang H.K.
        Screening and early detection of gastric cancer: east versus west.
        Surg Clin North Am. 2015; 95: 1053-1066
        • Chan W.L.
        • Lam K.O.
        • Lee V.H.F.
        • et al.
        Gastric cancer: from aetiology to management: differences between the east and the west.
        Clin Oncol (R Coll Radiol). 2019; 31: 570-577
        • Ngamruengphong S.
        • Abe S.
        • Oda I.
        Endoscopic management of early gastric adenocarcinoma and preinvasive gastric lesions.
        Surg Clin North Am. 2017; 97: 371-385
        • Yao K.
        The endoscopic diagnosis of early gastric cancer.
        Ann Gastroenterol. 2013; 26: 11-22
        • Graham D.Y.
        • Schwartz J.T.
        • Cain G.D.
        • et al.
        Prospective evaluation of biopsy number in the diagnosis of esophageal and gastric carcinoma.
        Gastroenterology. 1982; 82: 228-231
        • Kim J.W.
        • Shin S.S.
        • Heo S.H.
        • et al.
        Diagnostic performance of 64-section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual.
        Eur Radiol. 2012; 22: 654-662
        • Kim J.W.
        • Shin S.S.
        • Heo S.H.
        • et al.
        The role of three-dimensional multidetector CT gastrography in the preoperative imaging of stomach cancer: emphasis on detection and localization of the tumor.
        Korean J Radiol. 2015; 16: 80-89
        • Dassen A.E.
        • Lips D.J.
        • Hoekstra C.J.
        • et al.
        FDG-PET has no definite role in preoperative imaging in gastric cancer.
        Eur J Surg Oncol. 2009; 35: 449-455
        • Chen J.
        • Cheong J.H.
        • Yun M.J.
        • et al.
        Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
        Cancer. 2005; 103: 2383-2390
        • Stahl A.
        • Ott K.
        • Weber W.A.
        • et al.
        FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings.
        Eur J Nucl Med Mol Imaging. 2003; 30: 288-295
        • Sarela A.I.
        • Lefkowitz R.
        • Brennan M.F.
        • et al.
        Selection of patients with gastric adenocarcinoma for laparoscopic staging.
        Am J Surg. 2006; 191: 134-138
        • Bentrem D.
        • Wilton A.
        • Mazumdar M.
        • et al.
        The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection.
        Ann Surg Oncol. 2005; 12: 347-353
        • Mezhir J.J.
        • Shah M.A.
        • Jacks L.M.
        • et al.
        Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients.
        Ann Surg Oncol. 2010; 17: 3173-3180
        • Cunningham D.
        • Allum W.H.
        • Stenning S.P.
        • et al.
        Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
        N Engl J Med. 2006; 355: 11-20
        • Al-Batran S.E.
        • Homann N.
        • Pauligk C.
        • et al.
        Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
        Lancet. 2019; 393: 1948-1957
        • Postlewait L.M.
        • Maithel S.K.
        The importance of surgical margins in gastric cancer.
        J Surg Oncol. 2016; 113: 277-282
        • Japanese Gastric Cancer Association
        Japanese gastric cancer treatment guidelines 2014 (ver. 4).
        Gastric Cancer. 2017; 20: 1-19
        • Bozzetti F.
        • Marubini E.
        • Bonfanti G.
        • et al.
        Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group.
        Ann Surg. 1999; 230: 170-178
        • Mita K.
        • Ito H.
        • Fukumoto M.
        • et al.
        Surgical outcomes and survival after extended multiorgan resection for T4 gastric cancer.
        Am J Surg. 2012; 203: 107-111
        • Brar S.S.
        • Seevaratnam R.
        • Cardoso R.
        • et al.
        Multivisceral resection for gastric cancer: a systematic review.
        Gastric Cancer. 2012; 15: S100-S107
        • Macdonald J.S.
        • Smalley S.R.
        • Benedetti J.
        • et al.
        Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
        N Engl J Med. 2001; 345: 725-730
        • Schwarz R.E.
        • Smith D.D.
        Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage.
        Ann Surg Oncol. 2007; 14: 317-328
        • Biondi A.
        • D'Ugo D.
        • Cananzi F.C.
        • et al.
        Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?.
        Eur J Surg Oncol. 2015; 41: 779-786
        • Hoshi H.
        Standard D2 and modified nodal dissection for gastric adenocarcinoma.
        Surg Oncol Clin N Am. 2012; 21: 57-70
        • Songun I.
        • Putter H.
        • Kranenbarg E.M.
        • et al.
        Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.
        Lancet Oncol. 2010; 11: 439-449
        • Sano T.
        • Sasako M.
        • Mizusawa J.
        • et al.
        Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma.
        Ann Surg. 2017; 265: 277-283
        • Degiuli M.
        • Sasako M.
        • Ponti A.
        Morbidity and mortality in the Italian Gastric Cancer Study Group randomized clinical trial of D1 versus D2 resection for gastric cancer.
        Br J Surg. 2010; 97: 643-649
        • Degiuli M.
        • Sasako M.
        • Ponti A.
        • et al.
        Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer.
        Br J Surg. 2014; 101: 23-31
        • Cuschieri A.
        • Weeden S.
        • Fielding J.
        • et al.
        Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.
        Br J Cancer. 1999; 79: 1522-1530
        • Bonenkamp J.J.
        • Hermans J.
        • Sasako M.
        • et al.
        Extended lymph-node dissection for gastric cancer.
        N Engl J Med. 1999; 340: 908-914
        • Bonenkamp J.J.
        • Hermans J.
        • Sasako M.
        • et al.
        Quality control of lymph node dissection in the Dutch randomized trial of D1 and D2 lymph node dissection for gastric cancer.
        Gastric Cancer. 1998; 1: 152-159
        • Lee J.H.
        • Ryu K.W.
        • Lee J.H.
        • et al.
        Learning curve for total gastrectomy with D2 lymph node dissection: cumulative sum analysis for qualified surgery.
        Ann Surg Oncol. 2006; 13: 1175-1181
        • Parikh D.
        • Johnson M.
        • Chagla L.
        • et al.
        D2 gastrectomy: lessons from a prospective audit of the learning curve.
        Br J Surg. 1996; 83: 1595-1599
        • Tsujinaka T.
        • Sasako M.
        • Yamamoto S.
        • et al.
        Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501).
        Ann Surg Oncol. 2007; 14: 355-361
        • Cats A.
        • Jansen E.P.M.
        • van Grieken N.C.T.
        • et al.
        Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
        Lancet Oncol. 2018; 19: 616-628
        • Park S.H.
        • Sohn T.S.
        • Lee J.
        • et al.
        Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses.
        J Clin Oncol. 2015; 33: 3130-3136
        • Leong T.
        • Smithers B.M.
        • Michael M.
        • et al.
        TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
        BMC Cancer. 2015; 15: 532
        • Leong T.
        • Smithers B.M.
        • Haustermans K.
        • et al.
        TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG.
        Ann Surg Oncol. 2017; 24: 2252-2258
        • Slagter A.E.
        • Jansen E.P.M.
        • van Laarhoven H.W.
        • et al.
        CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
        BMC Cancer. 2018; 18: 877
        • Davis J.L.
        • Selby L.V.
        • Chou J.F.
        • et al.
        Patterns and predictors of weight loss after gastrectomy for cancer.
        Ann Surg Oncol. 2016; 23: 1639-1645
        • Aoyama T.
        • Yoshikawa T.
        • Shirai J.
        • et al.
        Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
        Ann Surg Oncol. 2013; 20: 2000-2006